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Abstract: SARS-CoV-2 infection represents a global threat to human health. Various approaches were
employed to reveal the pathogenetic mechanisms of COVID-19. Mathematical and computational
modelling is a powerful tool to describe and analyze the infection dynamics in relation to a plethora
of processes contributing to the observed disease phenotypes. In our study here, we formulate and
calibrate a deterministic model of the SARS-CoV-2 life cycle. It provides a kinetic description of the
major replication stages of SARS-CoV-2. Sensitivity analysis of the net viral progeny with respect to
model parameters enables the identification of the life cycle stages that have the strongest impact on
viral replication. These three most influential parameters are (i) degradation rate of positive sense
vRNAs in cytoplasm (negative effect), (ii) threshold number of non-structural proteins enhancing
vRNA transcription (negative effect), and (iii) translation rate of non-structural proteins (positive
effect). The results of our analysis could be used for guiding the search for antiviral drug targets to
combat SARS-CoV-2 infection.
Keywords: SARS-CoV-2; intracellular replication; mathematical model; sensitivity analysis; targets
for drugs
1. Introduction
Human infection with SARS-CoV-2 presents a tremendous health problem. The
within-host infection characteristics are characterized by extreme variability of the disease
course ranging from asymptomatic infections to severe forms of COVID-19 with lethal
outcomes [1]. This spectrum of pathogenicity is a result of the interaction of numerous
processes and factors on multiple levels of realization: the single cell, tissues and organs,
and the organism’s physiology [2]. The SARS-CoV-2 infection dynamics in a human organ-
ism is determined by the kinetics of infection of cells which express viral receptors (e.g.,
ACE2), by the activation of the intracellular defense, and by systemic immunophysiological
reactions. The corresponding “virus–human organism” is a multiscale, multicomponent
dynamical system. A comprehensive study of such a system requires the development of
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mathematical models that integrate the underlying biophysical, biochemical, and physio-
logical processes [3]. Although a few mathematical models have been recently proposed to
describe the within-host kinetics of SARS-CoV-2 infection [4–9], the degree of a mechanistic
process resolution remains to be greatly enhanced.
From a scientific point of view, the intracellular replication of the viruses is realized
as an intertwined set of biochemical reactions and biophysical transport processes. Being
summarized in a schematic form, the theoretical abstraction of the system provides a con-
ceptual platform for deriving a mathematical model. The mathematical descriptions can
further be specified on the basis of the law of mass action, enzyme kinetics, diffusion laws,
etc, following deterministic, stochastic, or hybrid approaches. The derived mathematical
models which bear a direct resemblance to and coordination with the underling chemical
and physical processes are considered as mechanistic models versus empirical (e.g., sta-
tistical) or black-box (e.g., neural-networks) type mathematical models. The mechanistic
models provide a descriptive and analytical tool for studying the virus life cycle regulation
and predicting its response to structural or parametric perturbations. In virology, the mech-
anistic models have been successfully developed and applied to study, in a quantitative
way, the intracellular replication of HIV-1 [10], hepatitis B virus [11], influenza A virus [12],
hepatitis C virus [13], and poliovirus [14].
The dynamic view on the balance between virus expansion and development of antivi-
ral immune responses suggests that the kinetics of virus growth is one of the major determi-
nants of the infection trajectory [15]. Existing mathematical models of SARS-CoV-2 infection
consider the virus growth at the cell population level, ignoring details of the virus life cycle.
The infection of permissive cells by the virus results in a number of dramatic changes of
the infected cell physiology, such as modification of host protein synthesis [16], inhibition
of the innate immune responses [17], and induction of programmed cell death [18]. In this
study, we formulate a mathematical model of SARS-CoV-2 replication in infected cells. The
development of the model follows a deterministic approach, similar to [10], in order to
focus on the calibration of model parameters to reproduce some reference kinetics of the
virus life cycle steps. By applying a sensitivity analysis of the model, we rank the model
parameters according to their impact on the net secretion of virions by the infected cell. The
most influential parameters can be considered as prospective targets for available antiviral
drugs or novel treatments.
2. Methods
2.1. Model Development and Calibration
The kinetics of the corresponding biochemical reactions is described in the determin-
istic mathematical model introduced in Section 3. The system of ordinary differential
equations (ODEs) is formulated using the law of mass action and Michaelis–Menten param-
eterization. Note that the deterministic version provides an initial step toward a stochastic
description of virus replication.
We use a Michaelis–Menten-type description for the nucleocapsid formation and viral
assembly processes to represent the following aspects of virus replication: (i) purified
coronavirus virions containing mainly full-genome length viral RNAs, i.e., there is no
saturation in the kinetics with respect to viral RNA [18], (ii) structural proteins (N and M)
required for virion morphogenesis and recruitment of the virion structural components
to the assembly site [1] scale this rate so that enough proteins must be present above a
certain level to reach half the maximal rate of the ribonucleoprotein formation and virion
assembly, and (iii) the least abundant structural proteins represent the kinetic bottleneck in
the overall progeny production.
A major step in the mathematical model formulation is the estimation of parameters
appearing on the right-hand sides of the model equations. The maximum likelihood
approach represents a general framework to address the parameter estimation problem.
However, the sparsity of the available kinetic data on the intracellular life cycle of SARS-
CoV-2 motivates the implementation of the parameter estimation procedure, which we
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refer to as “model calibration”. It stands for an iterative process of parameter guessing
and constraining the choice progressively by requiring consistency with all available
data. In this study, these data mainly consist of previously estimated numerical values
and/or numerical ranges of the molecular species variables at key time points, such as
the beginning and end of the infection cycle, or of intermediate steps, as summarized in
Table 1.
Table 1. Time-dependent variables of the mathematical model characterizing the SARS-CoV-2
life cycle.
Variable Meaning Quantitative Characteristics
[Vf ree] number of free virions outside the cell membrane 10
[Vbound]
number of virions bound to ACE2
and activated by TMPRSS2 1–10
[Vendosome] number of virions in endosomes 1–10
[gRNA(+)] single strand positive sense genomic RNA 1–5
[NSP] population of non-structural proteins −
[gRNA(−)] negative sense genomic and subgenomic RNAs 10
[gRNA] positive sense genomic and subgenomic RNAs 10,000
[SP] total number of structural proteinsS + M + E per virion 2000 ∈ (1125, 2230) [19–21]
[N] N proteins per virion [N] 456 [21]; 1465 ∈ (730, 2200) [19]
[N-gRNA] ribonucleocapsid molecules −
[Vassembled] assembled virions in endosomes −
[Vreleased] virus burst size 10–10,000 virions in 7 to 24 h [2,22,23]
2.2. Model Validation
To validate the calibrated model, we compared some predicted quantities with avail-
able experimental data, namely, (i) the kinetics of positive- to negative-sense vRNA ratio in
MHV-infected cells [24], and (ii) the kinetics of SARS-CoV-2 replication in the cell cultures
of Vero E6 cells [23,25]. As we cannot directly infer the absolute values of the number of
released virions by an infected cell just because there are no such single-cell experiments,
we used the relative measure of fold changes of titer levels in cell culture from the start of
their exponential growth. This data was compared with the fold changes of [Vreleased](t)
starting from the moment ts at which [Vreleased](ts) = 1.
The experimental data presented in [24] characterize the kinetics of virus transcription
and translation of cells infected with Murine coronavirus (MHV-A59). In particular, the
ribosome profiling technique was used to generate high precision data on the production
of the positive and negative-sense genomic and subgenomic viral RNAs. The overall
kinetics of SARS-CoV-2 in Vero E6 cells is studied in [23]. To this end, one-step growth
(MOI = 5) of three recombinant (i.e., icSARS-CoV-Urbani, icSARS-CoV-GFP, icSARS-CoV-
nLuc) and one clinical strain WA1 was followed. The data on the kinetics of virus titers
in the supernatants of cell cultures (PFU/mL) show that the growth phase until reaching
the plateau takes about 12 to 19 h and is similar to all the above CoV variants. A similar
study of SARS-CoV-2 replication features such as growth kinetics, virus titers, analysis
of transcription, and translation in Vero E6 cells is presented in [25]. The virus isolate
SARS-CoV-2 Australia/VIC01/2020 was used for infection of cells at MOI = 3. Intracellular
viral RNA, protein synthesis and release of infectious viral progeny (by plaque assay) were
quantified. The initial guess for the mathematical model parameters was specified using
data from a broad spectrum of publications covering the structural and genetic properties
of the SARS-CoV-2, the coronavirus transcription and translation, and the turnover of
proteins and RNA in cells with the relevant references presented in Section 3.
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2.3. Parameter Uncertainty Analysis
Through the process of model calibration, the point estimates of parameter values
were determined, which were used in main simulations and are discussed in Section 3.
For most of the model parameters, we were able to estimate the ranges of biologically
plausible values based on literature data. For other parameters, we derived their ranges
applying the parameter uncertainty analysis. To this end, we iteratively adjusted their
parameter ranges so that they would include their point estimates while the uncertainty
of the model output (progeny release kinetics) would be confined within the range from
10 to 10,000 virions, as specified in Table 1. For some parameters with wide literature-
based ranges, we further narrowed them down to restrict the output uncertainty. These
three categories of parameter ranges (based on literature analysis, based on uncertainty
analysis, based on both types of analysis), as well as parameters which are fixed ad hoc,
are reviewed in Section 3 accordingly. To quantify the output uncertainty, we employed
the Latin hypercube sampling method to randomly sample n = 10,000 combinations of
parameters from their respective ranges. Then, the median and 5–95% confidence regions
of the obtained ensemble of [Vreleased](t) trajectories were computed.
2.4. Sensitivity Analysis
Let u(t, p) be the model solution of the ODE initial value problem dudt = f(t, u, p),
u(0) = u0. In this study, we apply the methods of local sensitivity analysis to identify the
parameters (and respective biochemical processes) that have the most strong impact on the














The sensitivity index of model parameter p is defined as sp =
dΦ(p)
dp . It indicates the
influence of parameter variation on the output value Φ. To compare sensitivities and rank
parameters by their impact, the sensitivity indices are usually normalized by parameter
values: ŝp = p
dΦ(p)
dp . The sensitivity indices can be computed by solving the forward
sensitivity ODE system or by solving the adjoint problem [26]. We follow the adjoint-based
approach as previously described [10,26].
2.5. Software
The following packages in Julia language (https://julialang.org, accessed on
12 May 2021) were used to simulate and analyze the model: DifferentialEquations.jl (ac-
cessed on 12 May 2021) for numerical solution of the model, QuasiMonteCarlo.jl (accessed
on 12 May 2021) for parameter uncertainty analysis, DiffEqSensitivity.jl (accessed on
12 May 2021) for local sensitivity analysis, PyPlot.jl (accessed on 12 May 2021) for vi-
sualizations. The scripts used to simulate and analyze the model are provided in the
Supplementary Materials.
3. Results
We follow the latest view of the SARS-CoV-2 life cycle summarized in [1,17,18,27]. The
key steps include: (i) cell entry, (ii) genome transcription and replication, (iii) translation of
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structural and accessory proteins, and (iv) assembly and release of virions (Figure 1). The
set of time-dependent molecular species described in the model is listed in Table 1 with































Figure 1. Biochemical scheme of the SARS-CoV-2 replication cycle.
3.1. Mathematical Model of Intracellular SARS-CoV-2 Replication
3.1.1. Cell Entry
The entry stage of SARS-CoV-2 is split into three steps as represented in Figure 1:
1. binding of the receptor-binding domain (RBD) of the viral S protein to the ACE2 receptor,
2. priming by host cell surface protease TMPRSS2,
3. fusion at the cellular or endosomal membrane followed by release and uncoating of
the viral genomic RNA.
Binding of the virion to the cellular transmembrane protein ACE2, and entry and
release of the viral RNA into the host cell are described by equations specifying the rates of




= −kbind[Vf ree]− dV [Vf ree] + kdiss[Vbound] (1)
d[Vbound]
dt
= kbind[Vf ree]− (k f use + kdiss + dV)[Vbound] (2)
d[Vendosome]
dt
= k f use[Vbound]− (kuncoat + dendosome)[Vendosome] (3)
d[gRNA(+)]
dt
= kuncoat[Vendosome]− dgRNA[gRNA(+)]. (4)
Here, [Vf ree] is the number of free virions outside the cell membrane, [Vbound] is the
number of virions bound to ACE2 and activated by TMPRSS2, [Vendosome] is the number of
virions in endosomes, and [gRNA(+)] is the number of ss-positive sense genomic RNA.
The respective parameters of the above equations are described in Table 2. In estimating
the degradation rate of virions in endosomes, we followed the assumptions presented for
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modelling IAV infection [12], i.e., about 50% fail to release the viral genome. This gives
dendosome = 0.06 h−1.
3.1.2. Genome Transcription and Replication
The SARS-CoV-2 virion consists of about a 30 kb strand of positive sense RNA coated
with N protein and covered by a lipid bilayer containing spike S, membrane M, and
envelope E proteins [18]. The model was calibrated to reproduce (i) the scale of viral
proteins production corresponding to about 10 to 10,000 infectious virions per cell, (ii) the
observed ratio of positive and negative sense viral RNA (genomic and subgenomic) [24],
and (iii) the known ranges of the parameters of mRNA and protein turnover [28].
The released genomic RNA undergoes translation into viral polyproteins (pp1a, pp1ab)
which generate via proteolysis 16 non-structural proteins (nsp1–16). They are operating
to form the viral replication and transcription complex. In particular, a key step is the
formation of nsp12, which encodes the RNA-dependent RNA polymerase (RdRp). The
primary function of the RdRp replication complex is to generate a negative sense full-length
genome and subgenomic RNAs. It has been established for MHV virus that synthesis
of negative-sense RNA starts about 60 to 90 min post-infection and reaches a maximum
at about 5 to 6 h [24,29]. The resulting set of negative-sense RNAs and the full-length
antisense genome are working as templates for the synthesis of positive-sense genomic
and subgenomic RNAs as shown in Figure 1. The total number of produced positive-sense
viral genomes and subgenomic RNAs exceeds the number of negative-sense RNAs by 100
to 1000 fold [24,29].
We describe the abundance of the populations of non-structural proteins [NSP], the
set of negative sense genomic and subgenomic [gRNA(−)], and the set of positive sense
genomic and subgenomic [gRNA] with the following differential equations:
d[NSP]
dt
= ktransl fORF1[gRNA(+)]− dNSP[NSP] (5)
d[gRNA(−)]
dt
= ktr(−) [gRNA(+)]θRdRp − dgRNA(−) [gRNA(−)] (6)
d[gRNA]
dt









It is taken into account in Equation (5) that the non-structural proteins are translated
only from the released genomic RNA. Similarly, the transcription of the negative-sense
genomic and subgenomic RNA described by Equation (6) is determined by the original
positive-sense genomic RNA.
The translation rate ktransl = 45,360 nt/mRNA h−1 has been estimated for coro-
naviruses in [24]. The length of the RNA genome coding for [NSP] proteins is about
21,000 nucleotides [30], hence fORF1 = 1/21,000. These estimates are consistent with the
general range of protein synthesis rates: (1, 104) molecules/mRNA h−1 [28].
The degradation rate of NSPs dNSP = 0.069 h−1 is estimated as the geometric mean of
the half-lives of proteins in cells. This result of our calibration procedure is consistent with
the finding that the lifetime of most proteins is just a few hours [28].
The transcription rates of negative sense genomic and subgenomic RNAs is estimated
to be ktr(−) = 3 copies/mRNA h
−1. This is consistent with the transcription rate of mRNAs
which ranges from 1 to 100 copies per hour according to [28].
We assume the threshold for half-maximal rate of RdRp activity to be KNSP = 100 copies,
taking into account that a small number of non-structural proteins is sufficient for enhancing
the transcription of vRNAs.
It is known that an average half-life of mRNAs in cells of vertebrates is about 3 h [31]
and ranges from 1 to 10 h [28]. Hence, the decay rate of mRNAs can be in between
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[0.069, 0.69] h−1. We use here the following value dgRNA = 0.2 h−1. In addition, we assume
a smaller value for the degradation rate of negative sense vRNAs in double-membrane
vesicles, dgRNA(−) = dgRNA/2 = 0.1 h
−1.
Quantitative analysis of RNA polymerase elongation provides the estimate of the
transcription rate to be 46,080± 17,640 nt/h [32]. Thus, the basal rate of transcription is
around 46,080/30,000 nt/RNA h−1. In infected cells, however, the overall rate of viral RNA
transcription is amplified (around a 1000-fold increase) while transcription of host RNAs
is largely silenced [30]. Therefore, we estimate ktr(+) = 1000 copies/mRNA/h, which
matches the observed ratio of positive- to negative-sense viral RNAs [24,29] (see the model
validation results at the end of this Section).
The kinetics of the nucleocapsid formation (i.e., viral RNA genome coated with N
protein) resulting from the binding of N proteins and gRNA is characterized by the rate
constant kcomplex. This can be estimated from the binding data presented in [33]. The data
indicate a fast kinetics with a characteristic time of ≈20 s. Hence kcomplex ≈ 0.4 h−1, taking
into account that 1 virion consists of 38 ribonucleoprotein complexes each having about
12 N proteins [21], nN = 38× 12 = 456.
The kinetics of formation of the nucleocapsid condensates from N proteins and gRNA
has been studied in [34,35]. The minimum concentration of N proteins necessary to
form condensates has been estimated to be about 3.3 µM, and the concentration at which
the formation slows down to be about 11 µM. These concentrations correspond to ap-
proximately 1.5 and 5 million molecules, if we take 768 fL as the mean cell volume of
type II pneumocyte [2]. The estimate KN = 5× 106 molecules implies that the saturation
takes place at the number of N proteins necessary to assemble around 11,000 virions
(KN ≈ nN · 11,000).
3.1.3. Translation of Structural and Accessory Proteins
The structural proteins S, envelope E, and membrane M are translated from the
positive sense subgenomic RNAs at the endoplasmic reticulum (ER). They are described
in the model by their total abundance [SP]. They are considered to interact together and
assist in forming virus-like particles and budding of new virions from the ER and Golgi
compartments (ERIGC) [17]. The structural nucleocapsid protein N is translated from
subgenomic RNAs by cytosolic ribosomes and can enhance the formation of virus-like
particles [27]. Its key function is to create nucleocapsid [N-gRNA] by coating genomic
RNAs. The number of N proteins per virion [N] in coronaviruses is estimated to range
from 730 to 2200 [19]. For SARS-CoV-2, however, the estimated number of N proteins per
virion is nN = 38× 12 = 456 [21].
The translation rates of [N] and [SP] proteins are described by the following two equations:
d[N]
dt
= ktransl fN [gRNA]− kcomplexnNθcomplex[gRNA]− dN [N] (9)
d[SP]
dt




[SP] + KVrel nSP
(11)
The scaling parameter fN = 1/1200 accounts for the length of the N-coding RNA
which is about 1200 nucleotides (400 aa) [36]. Likewise, fSP = 1/10,000, as the estimated
RNA length for the structural proteins S, E, and M is about 10,000 nucleotides.
The degradation rate of N protein dN = 0.023 h−1 is estimated using the database [37].
The degradation rate of the mixture of other structural proteins is evaluated to be around
dSP = 0.044 h−1. The plausible range [0.023, 0.36] h−1 is guessed using the half-lives of
N, M, E, and S proteins being about 30 and 1.9 h, respectively, in reticulocytes, and their
relative molar ratio in a virion E:S:M = 1:20:300.
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The composition of a single virion requires the binding of about 456 N protein
molecules to each positive-sense genomic RNA, nN = 456. The total number of structural
proteins S, M, E can be estimated to be in between 1125 to 2230 [19–21] with the reference
number we used about 2000, i.e., nSP = 2000.
The scale of SARS-CoV-2 replication depends on the target cell type (e.g., bronchial,
lung cells, enterocytes). The available estimates suggest that the duration of the single repli-
cation cycle ranges from 7 to 24 h with the burst size in between 10 and 10,000 virions [2,22].
Hence, we set KVrel = 1000 ∈ (10, 10,000). Similar to modelling studies on replication of
HIV-1 [10] and IAV [12], we estimate the following range for the rate of virion assembling
kassemb = 0.01–10 h−1.
3.1.4. Assembly and Release of Virions
The assembly of virions requires that nucleocapsid and viral envelope glycoproteins
coalesce into the same domain of the intracellular space [18]. The nucleocapsid core of
the virion traffics to ERGIC and buds into ERGIC membranes covered with the structural
proteins. Thus, a lipid envelope of the virion is created. The genome packaging is mediated
by a packaging signal unique to genome length RNA.
As discussed above, the N proteins are key for incorporating viral RNA into viral
progeny particles [38,39]. There, the N-terminal RNA-binding domain binds the RNA
and the C-terminal domain via interaction with the M protein functions to anchor the
ribonucleoprotein to the viral membrane [40].
The virions are assembled at the ER-Golgi compartment via encapsulating N-RNA
complexes. Assembled new virions can exit the infected cell by exocytosis via the lysosomal
trafficking pathway, budding, or cell death [17].
The rates of changes of the ribonucleocapsid and the assembled and released virions
are described by the following equations:
d[N-gRNA]
dt
= kcomplexθcomplex[gRNA]− (kassembθassemb + dN-gRNA)[N-gRNA] (12)
d[Vassembled]
dt
= kassembθassemb[N-gRNA]− (krelease + dassembled)[Vassembled] (13)
d[Vreleased]
dt
= krelease[Vassembled]− dV [Vreleased] (14)
We use the estimate of dgRNA for dN-gRNA = 0.2 h−1, taking into account that the
major component of ribonucleoprotein is ssRNA.
The direct measurements of the budding rate are not available yet. However, it has
been shown for in vitro systems to be a very fast process with a characteristic time of about
2 s [41]. Hence, the following range is biologically plausible: krelease ∈ [8, 7200] h−1 [10].
As for the assembled virion death rate, we use the value dassembled = 0.06 h−1 estimated
from [42], which is equal to dendosome.
The overall list of model parameters with their reference values and permissible
ranges is presented in Table 2. The solution of the model described by Equations (1)–(14)
for [Vf ree](0) = 10 and the parameter values displayed in Table 2, is shown in Figure 2. It is
consistent with data presented in [24,43].
In this study, we analyze the model behaviour at the initial condition [Vf ree](0) = 10.
This corresponds to high MOI scenario of in vitro experiments in tissue cultures that are
performed to estimate the burst size, i.e., the average number of virions produced by a
single infected cell during the complete replication cycle. High MOI is typically used to
ensure that every single cell gets infected and therefore only a single replication cycle
occurs, resulting in a “one-step” growth dynamics of released progeny [2].
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Table 2. Estimates of the calibrated model parameters. The parameter range categories are labelled
as follows: ranges based on the analysis of (†) literature, (‡) uncertainty quantification, (†‡) both.
Parameter Description, Units Value Range, Relev. Refs.
kbind rate of virion binding to ACE2 receptor, h−1 12 (3.6, 12) † [44,45]
dV clearance rate of extracellular virions, h−1 0.12
(0.06, 3.5) † [42,46,47],
tuned to (0.06, 0.2) †‡
kdiss dissociation rate constant of bound virions, h−1 0.61 (0.32, 1.08) † [44,45]
k f use fusion rate constant, h−1 0.5 (0.33, 1) † [48]
kuncoat uncoating rate constant, h−1 0.5 (0.33, 1) † [48]
dendosome degradation rate of virions in endosomes, h−1 0.06 [12,42], (0.0001, 0.12) ‡
ktransl translation rate, nt/mRNA h−1 45,360
[24,28],
(40,000, 50,000) ‡
1/ fORF1 length of ORF1 of the RNA genome coding [NSP], nt 21,000 fixed [30]
dNSP degradation rate of proteins in the cell, h−1 0.069
(0.023, 0.69) † [28,37],
tuned to (0.023, 0.1) †‡
ktr(−)
transcription rate of negative sense
genomic and subgenomic RNAs, copies/mRNA h−1
3 (1, 100)
† [28],
tuned to (1, 20) †‡
KNSP
threshold number of [NSP]
enhancing vRNA transcription, molecules 100 (10, 150)
‡
dgRNA degradation rate of positive sense RNAs in cell, h−1 0.2
(0.069, 0.69) † [28,31],
tuned to (0.069, 0.4) †‡
dgRNA(−)
degradation rate of negative sense RNAs
in double-membrane vesicles, h−1
0.1 (0.05, 0.2) ‡
ktr(+) replication rate of positive sense RNAs, copies/mRNA/h 1000 (620, 1380)
† [32]
kcomplex rate of the nucleocapsid formation [N-gRNA], h−1 0.4 (0.02, 0.4) † [21,33,49–51]
KN
threshold number of N proteins
at which nucleocapsid formation slows down, molecules 5× 10
6 (3.5, 6.5)× 106 † [2,34,35]
1/ fN length of RNA genome coding N protein, nt 1200 fixed [36]
1/ fSP length of genome coding structural proteins S, E, M, nt 10,000 fixed [36]
dN degradation rate of N protein, h−1 0.023 (0.023, 0.069) † [37]
dSP mean degradation rate of the pool of E, S, M proteins, h−1 0.044 (0.023, 0.36) † [37]
nSP
total number of structural proteins S, M, E per virion,
molecules 2000 (1125, 2230)
† [19–21]
nN number of N protein per virion, molecules 456 fixed [21]
KVrel
threshold number of virions
at which the virion assembly process slows down, virions 1000 (10, 10,000)
† [2,22]
kassemb rate of virion assembling, h−1 1 (0.01, 10) † [10,12]
dN-gRNA degradation rate of ribonucleoprotein, h−1 0.2 (0.069, 0.69) † [28,31]
krelease rate of virion release via exocytosis, h−1 8 (8, 7200) † [10,41]
dassembled assembled virion degradation rate, h−1 0.06 [42], (0.0001, 0.12) ‡
The simulations cover the range of 24 h, which is informative for a single replication
cycle setting experimental data on SARS-CoV-2 replication [2,22,23]. However, the interval
can be stretched via amending the parameter values to adjust more specific data for
particular cell types and infection conditions (e.g., Figure 3, right).
The model is validated by comparing its predictions against available experimental
data as described in Methods section and shown in Figure 3.
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Figure 2. Reference model solution with parameters estimated in Table 2, [Vf ree](0) = 10. It predicts
the kinetics of the viral replication intermediates. The upper row describes the cell entry state
variables, i.e., (upper left) the free virions outside the cell membrane and the virions bound to ACE2,
and (upper right) virions in endosomes together with single strand positive sense genomic RNA.
The middle row specifies the kinetics of negative sense viral genome transcription and translation
of non-structural proteins (middle left) followed by the positive sense genomic RNA transcription
and the translation of N-protein (middle right). The bottom row displays the translation of the
structural proteins and the ribonucleocapsid molecules formation (bottom left) resulting in creation
of assembled virions in endosomes and the final release of virions (bottom right).
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Figure 3. Validation of the calibrated model against available experimental data. (Left) ratio of
positive- to negative-sense vRNA predicted by the model and measured in MHV-infected cells at
MOI = 10 in [24]. (Right) SARS-CoV-2 progeny release kinetics in Vero E6 cells from [23,25] expressed
in fold changes of the titer levels in cell culture from the start of their exponential growth. For model
predictions, the moment of release onset was defined as the moment ts at which [Vreleased](ts) = 1.
The initial conditions were chosen to match the MOI used in experiments, i.e., so that the maximum
number of uncoated [gRNA(+)] ≈MOI.
3.2. Sensitivity Analysis
To evaluate the model response to parameter variations, a systematic sensitivity
analysis of three model characteristics is performed. First, we assess the uncertainty of
predicted progeny release kinetics caused by variations of the initial condition and model
parameters in plausible ranges. Next, we identify the model parameters which have the
most control over (1) the ratio of positive- to negative-sense viral RNAs and (2) the total
number of virions released by 24 h post-infection.
3.2.1. Uncertainty Analysis of the Progeny Release Kinetics
As part of model validation, we assess the uncertainty of progeny release kinetics
caused by two factors. First, we predicted the changes in progeny trajectories obtained
with initial condition [Vf ree](0) varied by ±50%, i.e., from 5 to 15 virions (Figure 4 (left)).
Next, we quantified the model uncertainty caused by the changes of model parameters
(Figure 4 (right)). To this end, we randomly sampled a bunch of parameter combinations
from the ranges of their permissible values as described in the Methods section. Model
parameters presented in Table 2 can be either fixed ( fORF1, fN , fSP, nN) or allowed to be
varied. For most of the later parameters, their permissible ranges were estimated from
the literature. For parameters ktransl , densodome, KNSP, dgRNA(−) , dassembled, we estimated their
ranges so that the overall uncertainty of progeny release was matched with about 10 to
10,000 virions (i.e., 1000-fold range) in accordance with Table 1. However, we additionally
needed to narrow down the ranges of some parameters which were determined from
literature, i.e., dV , dNSP, ktr(−) , dgRNA, so that the confidence region of progeny release at
the end of replication cycle started from around ten virions but not from zero. As a result,
this procedure allows us to consistently identify the plausible ranges for model parameters
which ensure the robustness of the model behaviour in the range of its uncertainty that is
matched to the level of uncertainty coming from current knowledge about the SARS-CoV-2
life cycle.
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Figure 4. Uncertainty in the model output (progeny release kinetics). (Left) uncertainty associated
with variation of the initial condition [Vf ree](0). (Right) uncertainty associated with variation of
model parameters in the ranges specified in Table 2.
3.2.2. Parameters Controlling the Ratio of Positive- to Negative-Sense vRNAs
Given the good agreement of the calibrated model with available data on the kinetics
of positive- to negative-sense vRNA ratio (Figure 3), we asked which model parameters
determine this ratio. To this end, we analyze parameter sensitivity towards the following
distance Φratio(p) between the ratio predicted by the model rm(ti) and ratios rexp(1)(ti) and
















The nonzero normalized sensitivity indices towards Φratio are shown in Figure 5. The
following parameters have the largest effect on the discrepancy between the modelled and
experimentally obtained ratio of positive- to negative-sense vRNA:
• threshold number of [NSP] enhancing vRNA transcription,
• translation rate of non-structural proteins,
• rates of fusion and uncoating,
• replication rate of positive sense RNAs.
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Figure 5. Local normalized sensitivity indices having negative (left) and positive (right) effects on
the objective function Φratio(p), i.e., on discrepancy between model and experiment.
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3.2.3. Predicting Novel Antiviral Targets That Control Progeny Production
The calibrated model can be used to predict the sensitivity of SARS-CoV-2 production
by an infected cell to variations of the rates of underlying biochemical processes. To identify
the prospective antiviral targets, we analyze parameter sensitivity towards virus progeny
production. To this end, we use two functionals: (a) total number of released virions
during T = 24 hours post-infection, Φprogeny(p) =
∫ T
0 krelease[Vassembled]dt ≈ 280 virions,
and (b) the area under the curve type of metric for released virions during the same period,
ΦAUCprogeny(p) =
∫ T
0 [Vreleased]dt ≈ 1208 virions×hours. The sensitivity values, normalized by
parameter values, are presented in Figures 6 and 7. The left part of the figures ranks the
sensitivity indices for the model parameters that negatively impact the net SARS-CoV-2
production when their values are increased. The right bar plot ranks the sensitivity indices
for the parameters which positively affect the net virus production with their increasing
values. It follows that the three parameters having the largest sensitivity indices towards
both functionals are the following ones:
• degradation rate of positive sense vRNAs in cytoplasm (negative effect),
• threshold number of [NSP] enhancing vRNA transcription (negative effect),
• translation rate of non-structural proteins (positive effect).
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Figure 6. Local normalized sensitivity indices having negative (left) and positive (right) effect on the
total number of released virions Φprogeny(p).
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Figure 7. Local normalized sensitivity indices having negative (left) and positive (right) effect on the
area under the curve for released virions ΦAUCprogeny(p).
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4. Discussion
In this work, we have developed and calibrated a deterministic model of the SARS-
CoV-2 life cycle at the level of the infected cell. The mathematical model describes the
intracellular biochemistry underlying the replication of the virus. The model can be used
as a part of multiscale models of the within-host SARS-CoV-2 infection, which are expected
to provide a quantitative analytical tool to reveal complex pathogenetic mechanisms of
COVID-19 following a systems approach [3].
The developed model predicts the dynamics of intracellular replication cycle of SARS-
CoV-2 in target cells. The high initial condition of free infectious virions used in the paper
corresponds to in vitro experimental studies of viral replication cycle with high MOI. This
facilitates comparisons of model predictions of the dynamics of new viral progeny with
those that would be estimated in future experimental setups. In such high MOI conditions,
the entry of virions is very rapid [2]. In vivo, however, cells can be infected with a wide
ranging number of free virions. Moreover, the expression of ACE2 on epithelial cells of
various types and in different organs varies substantially [23,52], which would result in
different kinetics of the virus entry. Therefore, the density of ACE2 on a cell membrane
should be considered in the models of infection spreading within the human host organism.
Furthermore, the lower the MOI, the more prevalent are stochastic effects at the early
replication stages that result in the heterogeneity of the overall dynamics [53]. Thus, to
predict the virus transmission in vivo, the multiscale hybrid models need to be developed
that would incorporate the stochastic description of the intracellular SARS-CoV-2 life cycle.
Although many studies have been performed to characterize various aspects of the
SARS-CoV-2 life cycle, detailed kinetics data similar to those available for HIV-1 [54] do
not exist yet. Hence, the data “. . . to characterize the emergence of the viral replication
intermediates and their impact on the cellular transcriptional response with high temporal
resolution” [54] are urgently needed. In COVID-19, the virus infects multiple target cells
expressing ACE2 including type I and II pneumocytes, alveolar macrophages, monocytes,
endothelial cells, and airway epithelial cells, particularly of the mucous glands. To progress
further with the development of relevant multiscale mathematical models, all these cell
types need to be characterized with respect to the SARS-CoV-2 life cycle. For reviews on
experimental models which are developed to study SARS-CoV-2 replication in cultures of
various target cells, we refer to [55–58].
The deterministic quantitative description of the SARS-CoV-2 life cycle in the model
establishes a mechanistic basis for the development of a stochastic description of the process
kinetics using the Monte Carlo framework. This is required as many of the replication
stages are characterized by low numbers of reactants and hence, the impact of random
effects on the reaction kinetics is strong. The insight provided by stochastic models of
influenza, hepatitis, and HIV infections [12,59] can be utilized in a similar way for SARS-
CoV-2 modelling.
In our model, we do not consider spatial and transport aspects of the SARS-CoV-2
replication in the infected cell. An example of a stochastic approach to modelling the
intracellular spatio-temporal dynamics of HIV-1 replication describing the microtubule
transport of viral components is provided in [60]. In the case of SARS-CoV-2, adding the
spatial dimension to the model would include the creation of replication compartments
(e.g., double-membrane vesicles), intracellular trafficking (e.g., via the secretory pathway,
and the molecular interactions with host proteins and innate immune responses [17]. For
example, ORF3b, ORF6, and N proteins are known to interfere at multiple levels to inhibit
the IFN-signalling pathway. The accumulation of viral factors leading to infected cell
death via various mechanisms (apoptosis, necrosis, and pyroptosis) are not considered.
These all require further analysis and strongly depend on the availability of appropriate
quantitative data.
The developed mathematical model does not consider full details of subgenomic
RNAs transcription and translation processes, and hence, the interaction of the encoded
viral proteins with the intracellular defence mechanisms. The model needs to be linked to
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the cell physiology by considering the impact of virus infection on the codon usage, the
cell metabolism, and the infected cell fate.
At present, there are no effective therapies against SARS-CoV-2 infection and computa-
tional modelling is used to assist with drug repurposing attempts [27]. Here, we have used
our calibrated model to predict optimal targets for antiviral therapy. For this, all model
parameters were ranked according to their contribution to the production of new virions
by an infected cell using local sensitivity analysis. Parameters with the greatest negative
and positive effects on virus progeny generation were identified. The three most influential
parameters are (i) degradation rate of positive sense vRNAs in cytoplasm (negative effect),
(ii) threshold number of non-structural proteins enhancing vRNA transcription (negative
effect), and (iii) translation rate of non-structural proteins (positive effect). These parame-
ters regulate the kinetics of various stages of the SARS-CoV-2 life cycle. Overall, systematic
analyses of virus replication cycles with mathematical models of increasing level of detail
should provide an efficient and rational way to define novel antiviral targets for therapies.
A quantitative mathematical description of the SARS-CoV-2 life cycle is a necessary
step in gaining a predictive understanding of the regulatory mechanisms underlying
the molecular biology of the virus and defining potential targets for inhibitors of the
virus replication. Indeed, the sensitivity analysis of the model enables the prediction of
potential targets for further experimental consideration, thus assisting the drug discovery
or repurposing efforts. In fact, the derived model identifies such targets. The in silico
model provides an analytical tool to examine the effects of certain virus mutations (e.g., the
increase in affinity to ACE2 receptor) or combinations of multiple mutations on the viral
progeny and drug resistance in advance of experiments. Finally, the model of SARS-CoV-2
replication being properly expanded in a question-driven manner could assist in gaining
mechanistic insights into the robustness/fragility of intracellular defence mechanisms and
the net outcomes of multi-modal therapeutic impacts which affect the specific stages of
virus life cycle and the infected cell physiology.
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